Maintenance notice: Some features that submit or update information are temporarily disabled while we migrate the website. You can continue browsing normally. Thank you for your understanding.
July 6, 2017
A month after the U.S. Food and Drug Administration’s unprecedented request that a painkiller be taken off the market because of issues with abuse, Endo International has agreed to voluntarily stop selling Opana ER and recall the drug from the U.S. market.
The company “continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER…when used as intended, and notes that the company has taken significant steps over the years to combat misuse and abuse,” Endo said in a news release July 6.
Improving orthopaedic care, education and research using Internet technologies